Skip to content

Advertisement

Open Peer Review Reports for: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
25 Oct 2015 Submitted Original manuscript
4 Feb 2016 Reviewed Reviewer Report - Lekha Pandit
10 Feb 2016 Reviewed Reviewer Report - Vijayshree Yadav
3 Mar 2016 Reviewed Reviewer Report - Daniel M Harrison
15 Apr 2016 Author responded Author comments - Ralf Gold
Resubmission - Version 2
15 Apr 2016 Submitted Manuscript version 2
22 Jun 2016 Author responded Author comments - Ralf Gold
Resubmission - Version 3
22 Jun 2016 Submitted Manuscript version 3
Publishing
12 Jul 2016 Editorially accepted
26 Jul 2016 Article published 10.1186/s12883-016-0635-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement